###### Strengths and limitations of this study

-   Large cohort study of detailed growth patterns in extremely and very preterm infants.

-   A high number of infants in the earliest gestational ages enabling investigation of differences in growth patterns depending on gestational age at birth.

-   Advanced growth models comparing growth patterns generated in collaboration with a team of statisticians.

-   This study does not provide an answer to how the presently described associations are mediated.

Introduction {#s1}
============

An important challenge in the care of preterm infants is to reduce the incidence of neonatal and long-term morbidity.[@R1] [@R2] It is suggested that growth during the neonatal period should mimic intrauterine growth rates to enable normal organ development, but the optimal growth pattern for preterm infants is not known.[@R3] Intrauterine growth rates during the entire neonatal period are rarely achieved in extremely preterm infants.[@R4] [@R5]

Prenatal factors influence intrauterine maturation and growth, and intrauterine growth restriction (IUGR) increases the risks of abnormal organ development and disease.[@R6] Retinopathy of prematurity (ROP) is caused by abnormal postnatal retinal neurovascular development. Previous research has shown that ROP development is related to growth factor levels,[@R7] and that low gestational age (GA), associated with very immature retina as a starting point for postnatal growth, is the strongest risk factor for ROP development.[@R8] Small for gestational age (SGA) is a risk factor dependent on GA at birth.[@R9] Postnatal growth restriction has been used as a marker for ROP risk and is an important component of new surveillance systems developed to refine ROP screening.[@R10] Bronchopulmonary dysplasia (BPD) results from abnormal postnatal development of pulmonary tissue. It has been suggested that the biological processes that lead to ROP development also play important roles in BPD development.[@R17] BPD risk is also reportedly related to IUGR.[@R6] [@R18] [@R19] Necrotising enterocolitis (NEC) has been associated with IUGR and SGA, whereas intraventricular haemorrhage (IVH) has not.[@R6] [@R20] [@R21]

The present study aimed to describe how GA, birth weight and postnatal growth vary with the development of ROP, BPD, NEC and IVH in extremely preterm infants.

Patients and methods {#s2}
====================

This study used data from five cohorts of preterm infants from Canada, the USA and Sweden ([figure 1](#BMJOPEN2016012872F1){ref-type="fig"}). The Boston cohort included all infants born before 32 weeks GA and qualified for ROP screening at Brigham and Women\'s Hospital between 2005 and 2008.[@R12] The North American cohort originated from a multicentre study conducted between 2006 and 2009 at 10 level III neonatal intensive care units within the USA and Canada. This study aimed to validate the WINROP screening method.[@R13] EXPRESS is a population-based study including all infants born before 27 weeks GA between 2004 and 2007 in Sweden.[@R14] The Gothenburg cohort comprised infants born before 32 weeks GA and screened for ROP in Gothenburg between 2011 and 2012.[@R15] Our present study also included a previously unpublished population-based cohort of infants born before 27 weeks GA in Stockholm between 2008 and 2011.

![Flow chart of included cohorts. FEVR, familial exudative vitreoretinopathy; GA, gestational age; HC, hydrocephalus; PMA, postmenstrual age; w weeks.](bmjopen2016012872f01){#BMJOPEN2016012872F1}

Our present study included infants born at a GA of between 23+0 and 30+6 weeks without severe malformations, who survived to a postmenstrual age (PMA) of 40 weeks, and for whom data were available regarding birth weight (BW), maximum ROP stage and/or BPD. Exclusion criteria were hydrocephalus, which gave rise to non-physiological growth patterns, and more than two registered weight measurements that were considered to be unrealistic outliers based on age and relation to adjacent measurements. Data were collected as described in previous studies.[@R12] Data for infants in the Stockholm cohort were collected from hospital records. GA at birth was based on ultrasound dating or on the date of last menstrual period if no ultrasound had been performed.

Prenatal growth was evaluated as BW compared to the expected weight based on GA and gender. Comparisons were performed using a Swedish foetal growth reference constructed based on intrauterine ultrasound measurements,[@R22] which is considered to reflect undisturbed intrauterine growth. For comparison, the descriptive figure for growth also included reference lines from the Olsen growth chart, which is based on American live-born singletons.[@R23] Weight measurements were recorded weekly on average, with documentation of the exact date of every measurement. SGA was defined as BW below two SD scores according to the intrauterine growth reference.[@R22] ROP screening was performed following routine protocol, with classification according to the international system.[@R24] BPD was defined as need for oxygen at a PMA of 36 weeks.[@R25] NEC was defined as Bell stage 2b or greater.[@R26] IVH registration included any grade of IVH.

Statistics {#s2a}
----------

All statistical analyses were performed using Stata/IC V.13.1 software (StataCorp LP, College Station, Texas, USA). Data outliers were examined with the use of population and individual residuals in the model and excluded if deemed unrealistic. Level of significance was set at 5%. Descriptive analyses included quantile regression growth models. Differences in BW and birth weight standard deviation score (BWSDS) were estimated using a linear regression model with robust SEs. We applied a mixed effects model including restricted cubic splines (knots at 2, 4, 6 and 10 weeks), with random slope and intercept, to evaluate growth as weight and growth rate over time.[@R27] [@R28] Growth rates were calculated using the exponential model suggested by Patel *et al*.[@R29] In the mixed effects model, we included growth rates using all weights and calculated the mean between-group differences in weight and growth rate. To describe the overall growth rate in the entire cohort, we calculated the rate from birth weight to weight at 36 weeks PMA. If no measurement at 36 weeks PMA was available, we used the closest value up to 2 weeks prior.

All analyses were initially stratified by gestational week at birth. For the final analyses, participants were divided into three groups by GA: 23--24 weeks, 25--26 weeks and 27--30 weeks. The GA groups were selected based on the results of the 1 week analysis. Postnatal growth results are presented from birth until 36 weeks PMA. All analyses were adjusted for exact gestational age in days, gender and centre. Date of birth was also tested and eliminated as a confounder and therefore not included in the final model. When analysing differences in weight over time and growth rate in cases of ROP and BPD, we included further adjustment for NEC and BWSDS. Analyses were also tested for interaction regarding BWSDS and morbidity and country and morbidity, respectively. No significant association on differences in growth rate were found, and the interaction terms were not included in the final model. Selected adjustments were based on previously known influences, as well as statistical procedures, including backward selection.

Ethical statement {#s2b}
-----------------

The Swedish studies were approved by regional ethical review boards (Lund 2004-42; Stockholm 2007-1613312 and 2013-26532; Gothenburg 2013-051-13). The North American studies were approved by institutional review boards at all participating centres (Brigham and Women\'s Hospital, Boston, Massachusetts, USA; Beaumont Hospital/Associated Retinal Consultants, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Emory University Hospital Midtown, Emory University School of Medicine, Atlanta, Georgia, USA; Morristown Medical Center at Atlantic Health, Atlantic Neonatal Research Institute, Morristown, New Jersey, USA; Mount Sinai Hospital, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada; Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus; New York-Presbyterian Morgan Stanley Children's Hospital, Columbia University College of Physicians and Surgeons, New York, New York, USA; North Carolina Children's Hospital, University of North Carolina School of Medicine, Chapel Hill; UMass Memorial Medical Center, UMass Medical School, Worcester, Massachusetts, USA; Wilford Hall Medical Center, Uniformed Services University of the Health Sciences, Lackland Air Force Base, Texas, USA).

Results {#s3}
=======

This study included a total of 2521 infants ([figure 1](#BMJOPEN2016012872F1){ref-type="fig"}), with a mean of 14.3 weight measurements per infant (median, 11; IQR, 9--16). The last weight measurement was registered at a mean PMA of 37+6 weeks (median, 37+5 weeks; IQR, 36+0--39+5 weeks). Baseline characteristics are demonstrated in [table 1](#BMJOPEN2016012872TB1){ref-type="table"}. The infants\' gestational ages were evenly distributed between the early group (23--26 weeks; 52%) and the later group (27--30 weeks; 48%). The later GA group showed a lower median BWSDS. Infants born at GA 23--26 weeks showed significant postnatal growth restriction, reflected by a reduced mean weight SD score from birth to 36 weeks PMA, with the most pronounced difference among the more immature infants. [Figure 2](#BMJOPEN2016012872F2){ref-type="fig"} and [table 1](#BMJOPEN2016012872TB1){ref-type="table"} illustrate the growth data. Median weekly growth rates were highest at a PMA of 30 weeks in infants born at GA 23--26 weeks, and at a PMA of 31--34 weeks among infants born at GA 28--30 weeks, corresponding to the fifth week of life.

###### 

Infant characteristics, growth and morbidity by gestational age at birth

                               Gestational age at birth (weeks)                                                                                                                                                                                            
  ---------------------------- ---------------------------------- ------------ --------- ------------ --------- ------------ --------- ------------ --------- ------------ --------- ------------ --------- ------------ --------- ------------ ---------- ------------
  **Infants**                  **117**                            **4.6**      **314**   **12.5**     **399**   **15.8**     **482**   **19.1**     **249**   **9.9**      **296**   **11.7**     **323**   **12.8**     **341**   **13.5**     **2521**   **100**
  Female sex                   58                                 49.6         137       43.6         190       47.6         229       47.5         119       47.8         139       47.0         134       41.5         162       47.5         1168       46.3
  Country                                                                                                                                                                                                                                                  
   NA\*                        53                                 45.3         168       53.5         190       47.6         227       47.1         237       95.2         277       93.6         299       92.6         319       93.5         1770       70.2
   Sweden                      64                                 54.7         146       46.5         209       52.4         255       52.9         12        4.8          19        6.4          24        7.4          22        6.4          751        29.8
  SGA                          5                                  4.3          38        12.1         81        20.3         115       23.9         77        30.9         110       37.2         107       33.1         114       33.4         647        25.7
                               Mdn                                IQR          Mdn       IQR          Mdn       IQR          Mdn       IQR          Mdn       IQR          Mdn       IQR          Mdn       IQR          Mdn       IQR          Mdn        IQR
  BW (g)                       595                                550--655     675       610--735     770       693--858     890       776--995     989       865--1080    1071      921--1211    1287      1100--1420   1415      1195--1550   915        731--1153
  BWSDS (SDS)                  −0.4                               −1.0--0.4    −0.6      −1.4--0.0    −1.0      −1.7--0.1    −1.0      −2.0--0.2    −1.3      −2.3--0.6    −1.6      −2.6--0.8    −1.3      −2.3--0.4    −1.4      −2.5--0.6    −1.1       −2.0--0.3
  Weight at 36 weeks PMA (g)   2072                               1847--2263   2123      1932--2319   2126      1881--2377   2190      1905--2415   2244      1922--2501   2179      1958--2500   2320      1973--2582   2206      1902--2506   2157       1909--2391
  WSDS at 36 weeks PMA (SDS)   −2.3                               −2.9--1.8    −2.2      −2.8--1.6    −2.2      −2.9--1.4    −2.0      −2.9--1.2    −1.6      −2.7--0.8    −1.9      −2.5--0.9    −1.5      −2.6--0.7    −1.8      −2.9--0.9    −1.9       −2.7--1.2
  Growth rate† (g/kg/d)        13.7                               12.6--15.2   13.8      12.6--15.2   13.8      12.7--15.4   13.8      12.3--15.4   13.7      12.3--15.2   13.3      11.6--14.9   12.4      11.0--14.2   11.8      9.8--13.9    13.3       11.8--15.0
  MAX rate (g/kg/d)            18.9                               11.5--23.6   18.3      12.2--23.8   19.7      13.1--25.6   20.3      13.4--25.6   21.7      17.8--25.1   20.5      16.9--23.8   20.4      16.6--23.7   19.0      15.7--22.7   17.7       11.3--22.7
  PMA \@MAX                    30                                 30           30        30           31        32           33        34           31                                                                                                     
                               n                                  Per cent     n         Per cent     n         Per cent     n         Per cent     n         Per cent     n         Per cent     n         Per cent     n         Per cent     N          Per cent
  ROP‡                                                                                                                                                                                                                                                     
   No                          9                                  7.7          17        5.4          69        17.3         166       34.4         99        39.8         185       62.5         236       73.1         304       89.1         1085       43.0
   ROP 1--2                    40                                 34.2         131       41.9         215       54.0         236       49.0         127       51.0         98        33.1         84        26.0         34        10.0         965        38.3
   ROP≥3                       68                                 58.1         165       52.7         114       28.6         80        16.6         23        9.2          13        4.4          3         0.9          3         0.9          471        18.7
   Trt                         51                                 43.6         109       34.9         65        16.3         39        8.1          16        6.4          5         1.7          3         0.9          0         0.0          288        11.4
  BPD‡                         104                                88.9         247       79.2         289       72.8         308       64.6         124       49.8         108       36.5         58        18.0         30        8.8          1268       50.5
  NEC                          9                                  7.7          47        15.0         33        8.3          42        8.7          25        10.0         32        10.8         27        8.4          15        4.4          230        9.1
  All IVH                      60                                 51.3         144       45.9         141       35.3         118       24.5         65        26.1         56        18.9         64        19.8         44        12.9         692        27.4

\*North America (USA and Canada).

†Overall growth rate from birth to 36 weeks PMA calculated for 2344 infants.

‡Information regarding ROP was missing for one infant born at a gestational age of 24 weeks, and one infant at 25 weeks. Information regarding BPD was missing from two infants born at a gestational age of 24 weeks, two infants at 25 weeks and five infants born at 26 weeks.

BWSDS, birth weight SD score; BPD, bronchopulmonary dysplasia; IVH, intraventricular haemorrhage; Mdn, median; NEC, necrotising enterocolitis; PMA, postmenstrual age; ROP, retinopathy of prematurity; Trt, treatment for ROP; w, weeks. IQR (25th to 75th centile).

![Postnatal weight development and growth rate according to gestational age, illustrated by the 25th, 50th and 75th centiles. (A) Postnatal weight development in grams. (B) Postnatal growth rate in g/kg/day. Growth references 50th centiles from Marsal *et al*[@R22] and Olsen *et al.*[@R23] Pink denotes female, and blue male.](bmjopen2016012872f02){#BMJOPEN2016012872F2}

Morbidity {#s3a}
---------

[Table 1](#BMJOPEN2016012872TB1){ref-type="table"} displays the numbers and frequencies of ROP, BPD, NEC and IVH by gestational week. Differences in BWSDS, postnatal weight and growth rate are shown in [figured 3](#BMJOPEN2016012872F3){ref-type="fig"} and [4](#BMJOPEN2016012872F4){ref-type="fig"}, as well as in the online [supplementary appendix](#SM1){ref-type="supplementary-material"}.
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![Difference in BWSDS according to gestational age group, between infants with and without respective morbidities. Data are shown as mean and 95% CI for each diagnose. All analyses are adjusted for exact gestational age at birth, gender and centre. BPD, bronchopulmonary dysplasia; BWSDS, birth weight SD score; NEC, necrotising enterocolitis; IVH, intraventricular haemorrhage; ROP, retinopathy of prematurity.](bmjopen2016012872f03){#BMJOPEN2016012872F3}

![Difference in weight and in growth rate over time according to gestational age group, between infants with and without respective morbidities. (A) The difference in weight in grams. (B) The difference in growth rate in g/kg/day. Time is represented by PNA in weeks. Data are shown as mean and 95% CI for each diagnosis. All analyses are adjusted for exact gestational age at birth, gender and centre. Analyses of differences regarding ROP and BPD are also adjusted for NEC and in growth rate analyses for BWSDS. BPD, bronchopulmonary dysplasia; BWSDS, birth weight SD score; NEC, necrotising enterocolitis; IVH, intraventricular haemorrhage; PNA, postnatal age; ROP, retinopathy of prematurity.](bmjopen2016012872f04){#BMJOPEN2016012872F4}

ROP and growth {#s3b}
--------------

Infants developing ROP of any grade showed lower growth rates compared to infants not developing ROP. This difference was noted in the 7--9th weeks of life among infants born at GA 23--24 weeks, and in the 4--6th weeks of life in those born at GA 25--26 weeks. Infants born at GA 27--30 weeks had lower growth rates during their first 5 weeks of life, shifting to higher growth rates starting at the 7th week of life. Among infants born at GA 25--30 weeks, BWSDS was lower in infants developing ROP. Differences at birth were greater among infants born at later GA (see online [supplementary appendix figure S1 and table S1](#SM1){ref-type="supplementary-material"}).

BPD and growth {#s3c}
--------------

Among those born at GA 27--30 weeks, infants with BPD had lower growth rates in the 4--5th week of life compared to infants without BPD, followed by higher growth rates from the 7th week of life. Among those born at GA 23--24 weeks, infants developing BPD showed significantly lower weight during the 8--12th week of life compared to those without BPD, while these groups did not significantly differ in growth rate. Among those born at GA 25--30 weeks, BWSDS was lower in infants developing BPD. These differences were greater among infants born at later GA, and weight continued to be lower from birth to PMA 36 weeks (see online [supplementary appendix figure S2 and table S2](#SM1){ref-type="supplementary-material"}).

NEC and growth {#s3d}
--------------

Among infants born at all GAs, those with NEC showed lower growth rates from the 6--7th week of life and during the rest of the studied neonatal period compared to infants without NEC. Infants born at all GAs with and without NEC did not significantly differ in BWSDS (see online [supplementary appendix figure S3 and table S3](#SM1){ref-type="supplementary-material"}).

IVH and growth {#s3e}
--------------

Analysis of infants with any IVH compared to with no IVH revealed no associations with prenatal or postnatal growth (see online [supplementary appendix figure S4](#SM1){ref-type="supplementary-material"}).

SGA and postnatal growth {#s3f}
------------------------

Compared to infants born at a weight appropriate for their gestational age, those born SGA continued to show lower weights until 36 weeks PMA. For the first 3 weeks of life, SGA infants showed higher growth rates than appropriate for gestational age infants (see online [supplementary appendix figure S5](#SM1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This study demonstrates differences in postnatal growth patterns in infants developing morbidities and highlights specific postmenstrual weeks with greater differences in growth rates, potentially implicating important windows of vulnerability partly depending on GA. Our present results showed similar patterns of prenatal and postnatal growth restriction between infants developing ROP and BPD. Infants born at a GA of 25--30 weeks who developed ROP and BPD were smaller at birth. Infants born at all GAs who developed ROP had reduced growth rates. Among those born at GA 23--26 weeks, this reduction was most pronounced around the postnatal weeks corresponding to the 31st postmenstrual week. Those born at GA 27--30 weeks and developing ROP and BPD showed an initially reduced growth rate, which shifted to higher growth rates in later weeks. Infants developing NEC and IVH showed a different pattern of prenatal and postnatal growth restriction, indicating a different pathophysiology. The frequency of especially ROP and BPD is high among the most immature infants; 76% of the infants in GA 23--24 weeks developed ROP and BPD, which is important to bear in mind comparing the growth patterns between morbidities (see online [supplementary appendix table S4](#SM1){ref-type="supplementary-material"}).

To the best of our knowledge, this is the largest detailed study of postnatal weight development among low-gestational age infants, including a large proportion of extremely preterm infants. Stratification by GA rather than birth weight enables consideration of the increased morbidity risks associated with a greater degree of immaturity. The wide range of methods used to evaluate postnatal growth in previous studies makes it difficult to compare results among studies. In 1999, Ehrenkranz *et al*[@R4] described the postnatal growth pattern of infants developing morbidity, reporting a mean growth rate (from regaining BW to discharge, death or reaching 2 kg) of 14--16 g/kg/day, increasing with increasing GA. Horbar *et al*[@R30] reported growth rates calculated using the two-point exponential model from birth to discharge. The mean growth rates from 2013 in GA 24--26 weeks were 13.0 g/kg/day (95% CI 13.0 to 13.1). Martin *et al*[@R31] reported a relationship between lower BWSDS and higher growth rates during the first weeks of life that was similar to the association observed in our cohort. However, Martin *et al*[@R31] did not use an exponential growth model to calculate growth rates, resulting in higher rates compared to those found in our study. Our presently used exponential model has been evaluated and deemed most appropriate for calculating growth rates of preterm infants.[@R29] Fortes Filho *et al*[@R32] described a relationship between severe ROP and proportion of birth weight gained at 6 weeks of age. Their results are consistent with our findings in infants born at a GA of 25--30 weeks. Nyp *et al*[@R33] evaluated growth rate (in g/kg from BW to 36 weeks PMA) among 140 infants born before 28 weeks of GA and found no association with BPD. In our substantially larger cohort, we detected associations between BPD and postnatal growth that related to specific postnatal weeks.

Limitations of our present study include a lack of information regarding some perinatal background data preventing any conclusions regarding causality. Notably, our material included no information regarding sepsis. Ehrenkranz *et al*[@R4] demonstrated that infants with sepsis have growth pattern similar to those of infants with BPD. Moreover, the use of BWSDS to classify foetal growth restriction could lead to misclassification of infants who are genetically SGA without foetal growth restriction. Additionally, this study included only infants who survived to 40 weeks PMA, which could affect the description of postnatal growth within the entire cohort but not our main outcomes. The combined data set included no information regarding time of NEC. The fact that surgically managed NEC has been previously associated with substantial growth delay,[@R34] and the growth patterns demonstrated in our present results suggest that the NEC disease process precedes growth restriction. IVH---which usually occurs early postnatally---does not appear to be strongly related to postnatal growth. Caution is advised interpreting significant results in a study including multiple comparisons. This study examines growth in four morbidities in three strata of GA. The time is handled as a continuum; p values regarding differences in growth rates are presented week by week in the online [supplementary appendix](#SM1){ref-type="supplementary-material"}.

From this study, it is not possible to determine how the presently described associations are mediated. Analysis of the relationship between nutrition and ROP in the EXPRESS cohort revealed that low energy intake during the first 4 weeks of life was related to increased frequency of severe ROP, after adjustment for several morbidities.[@R35] Nutrition practices have most likely been continuously altered during the studied period of time. Including date of birth in the model did not alter the results, but the need to adjust for centre in the final model demonstrates that centre is associated with weight and disease development even adjusted for GA at birth and BWSDS and could be a reflection of differences in perinatal care. Both the pattern of initially reduced and later increased growth rates could be of importance for processes involved in the development of ROP and BPD. The specific weeks showing significantly reduced growth rates corresponded to a PMA of around 31 weeks in infants born at a GA of 23--26 weeks, implicating an especially important period of growth in extremely preterm infants. This is the period of maximum growth rate and represents the transition from growth failure to catch-up growth among infants born at these GAs. Hansen-Pupp *et al*[@R36] described increased insulin-like growth factor I (IGF-I) concentrations at PMA 30 weeks, coinciding with the initiation of catch-up growth. Moreover, ROP severity is correlated to IGF-I serum concentrations and duration of low IGF-I concentrations.[@R7] [@R37] The reduced growth rates at a PMA of around 30 weeks could be biologically related to initiation of phase II of ROP development, which has been demonstrated to correlate to an increase of the initially low levels of IGF-I.[@R7] Lower IGF-I levels in the first postnatal weeks are also associated with BPD among very preterm infants.[@R17] It is reasonable to postulate that factors that control somatic growth also influence retina and lung development. ROP is a vascular and neurological disease. Poor neurodevelopment has been related to poor postnatal growth,[@R38] [@R39] and postnatal IGF-I concentrations have been associated with brain volume at term.[@R40] Neonatal care should aim at optimal growth during the entire neonatal period. Future clinical trials should further investigate the specific periods of slower growth rates and catch-up growth and continue to analyse interactions between growth factors, nutrition, weight gain and morbidities, including neurodevelopmental outcomes. Our present results highlight postnatal growth as a marker for disease, emphasising the importance of monitoring growth and nutrition in the neonatal intensive care unit.

**Contributors:** SK collected data from the Stockholm cohort, carried out the analyses, drafted the initial manuscript, revised the manuscript and approved the final manuscript as submitted. PL and CL coordinated the data collection, contributed to the design of the study, reviewed the manuscript and approved the final manuscript as submitted. UH and MB merged the data sets, participated in selection of statistical methods, carried out the initial analyses and approved the final manuscript as submitted. LES and MD coordinated and supervised data collection from the American cohorts and Swedish national cohort, respectively, reviewed the manuscript and approved the final manuscript as submitted. BH contributed to the design of the study, critically reviewed the manuscript and approved the final manuscript as submitted. AH conceptualised and designed the study, supervised data collection, reviewed the manuscript and approved the final manuscript as submitted.

**Funding:** This study is supported by grants provided by Swedish Research Council (DNR number 2011-2432) and Gothenburg County Council (ALFGBG-426531). SK was supported by the Stockholm County Council (combined clinical residency and PhD training programme) and has received grants from Lilla Barnets Fond, Stiftelsen Samariten and Föreningen Mjölkdroppen. LES was supported by NIH EY024864, EY017017, EY022275, P01 HD18655, Lowy Medical Research Institute, European Commission FP7 project 305485 PREVENT-ROP.

**Competing interests:** None declared.

**Ethics approval:** Lund 2004-42; Sthlm 2007-1613312 and 2013-26532; Gbg 2013-051-13; North American studies were approved by institutional review boards at all participating centres (specified in the text).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** No additional data are available.
